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Caveolin-1 is a major structural component of caveolae, which are plasma membrane microdomains implicated in the
regulation of intracellular signalling pathways. Previous in vitro and in vivo studies on the function of caveolin-1 in carcinoma
showed controversial results, indicating that the physiological role of caveolin-1 varies according to the origin of carcinoma. In
this study, we investigated caveolin-1 expression in thyroid neoplasms by means of immunohistochemistry using a rabbit
polyclonal antibody against caveolin-1. Normal follicular cells did not express caveolin-1. In papillary carcinoma, caveolin-1
expression was observed in high incidence, and especially in microcancer (less than 1.0 cm in diameter), caveolin-1 was
positive in all cases except one. In undifferentiated (anaplastic) carcinoma, its incidence was signiﬁcantly reduced. On the other
hand, all cases of follicular carcinoma and adenoma were classiﬁed as negative for caveolin-1. These results suggest that
caveolin-1 may play a role predominantly in the early phase of papillary carcinoma, whereas it has little inﬂuence on follicular
tumours.
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Caveolin-1isa22 kDaproteinandaprominentmemberofthecaveo-
lin family. This protein is a major structural component of caveolae,
which are the vesicular invaginations of the plasma membrane, and
isabundantlypresentinvascularendothelialcells,adipocytes,smooth
muscle cells and ﬁbroblast (Harter and Simons, 1997; Okamoto et al,
1998). Previous studies have demonstrated that the caveolin family
contains a common domain, a caveolin-scaffolding domain which
organises and concentrates sphingolipids and lipid-modiﬁed signal-
ling molecules (Song et al, 1997a). The function of caveolin-1 has
been investigated by previous studies, which showed that caveolin-1
inhibitsintracellularsignaltransduction modulatedbyvarioussignal-
ling molecules (Li et al, 1995; Couet et al, 1997; Garcia-Cardena et al,
1997; Song et al, 1997b; Engelman et al, 1998a; Lui et al, 1999).
The caveolin-1 gene is located at human chromosome 7q31.1,
and this region is frequently deleted in carcinomas (Engelman et
al, 1998b). The expression of caveolin-1 protein in carcinomas
has also been studied. Thus far, a decreased expression of caveo-
lin-1 has been found in a variety of cell lines such as those of
breast carcinoma (Lee et al, 1998), lung carcinoma (Racine et al,
1999), sarcoma (Wiechen et al, 2001), uterine cervical carcinoma
(Razani et al, 2000), and colon carcinoma (Bender et al, 2000).
Furthermore, re-expression of caveolin-1 inhibited the growth of
breast carcinoma cells (Lee et al, 1998) and colony formation of
sarcoma cells (Razani et al, 2000) and ectopic caveolin-1 expression
reduced tumorigenecity of colon carcinoma cells (Bender et al,
2000). These results suggest that the caveolin-1 gene may be a
candidate as a tumour suppressor gene as its gene product func-
tions as a negative regulator of tumour progression.
On the other hand, the results of studies for caveolin-1 expres-
sion using human carcinoma tissue have been different from those
using cell lines. Yang et al (1998) showed that the expression of
caveolin-1 was elevated in breast and prostate carcinomas and,
especially in prostate carcinoma, caveolin-1 expression was more
frequently observed in cases with high biological aggressiveness
including poor prognosis (Yang et al, 1999). Furthermore, caveo-
lin-1 expression was more membranous in ovarian carcinoma
with short-term survival (Davidson et al, 2001). In colon carcino-
ma, caveolin-1 expression increased compared to normal
epithelium, but it was not linked to the stage (Fine et al, 2001).
These results indicate that caveolin-1 has some functions other
than as a negative regulator of tumour progression, and its physio-
logical role in carcinoma is complicated depending on the origin of
the carcinoma and other various circumstances.
Thyroid carcinoma is one of the most common malignancies
originating from the endocrine organs. There are two prominent
histological types of thyroid carcinoma originating from the folli-
cular cells. One is papillary carcinoma and the other is follicular
carcinoma, which is comparatively rare (LiVolsi and Asa, 1994).
Generally, the biological character of these carcinomas is mild,
but when they dedifferentiate and become anaplastic (undifferen-
tiated), their growing activity is very strong and patients usually
have a dire prognosis, in spite of various therapeutic strategies.
These polarised characteristics of thyroid carcinoma have
prompted many researchers to study the factors linked to the
dedifferentiation of papillary and follicular carcinomas. In this
study, we investigated caveolin-1 expression in various types of
thyroid neoplasm in order to clarify its role, including this point.
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Tissue specimens
Tissue specimens of thyroid neoplasms were obtained from 161
patients who underwent surgery in the Department of Surgery,
Kuma Hospital. These consisted of 32 anaplastic (undifferentiated)
carcinomas, 85 papillary carcinomas, 15 widely invasive and eight
minimally invasive follicular carcinomas and 11 follicular adeno-
mas. The patients with anaplastic carcinoma were operated on
from 1983 to 2001, and those with widely invasive follicular carci-
noma from 1995 to 2001. Other cases were selected from patients
who underwent surgery from 1999 to 2001. Of the 85 papillary
carcinomas, 23 were microcancers which were less than 1.0 cm
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Figure 1 (A) Caveolin-1 is negative in normal follicular cells. (B) Caveolin-1 expression in microcancer. This case was classiﬁed as (+++). (C) Caveolin-1
expression in type A papillary carcinoma classiﬁed as (++). (D,E) Caveolin-1 is negative in type B papillary (D) and undifferentiated carcinomas (spindle cell
type) (E). (F) Caveolin-1 is negative in this follicular carcinoma, minimally invasive type. Scale bars, 33 mm.
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found in specimens of other diseases such as hyperthyroidism,
adenomatous goiter and follicular adenoma. We divided the
remaining papillary carcinoma cases into two categories, type A
and type B. Type A papillary carcinoma is composed of pure papil-
lary structure, whereas type B carcinoma has any one of the
components showing a solid, trabecular or scirrhous growth
pattern. For immunohistochemical study, the tissues were ﬁxed
with 10% formalin and parafﬁn-embedded. This project was
approved by the ethics committees of the hospital and informed
consent was obtained from the participating patients.
Antibodies
We adopted a rabbit polyclonal antibody against caveolin-1 (N-20)
at a dilution of 1:300 as the primary antibody, obtained from Santa
Cruz Biotechnology (Santa Cruz, CA, USA).
Immunohistochemistry
Tissue sections 4 mm thick were dewaxed and endogenous peroxi-
dase activity was blocked with 0.3% hydrogen peroxide in
methanol for 15 min. After rinsing in distilled water, the sections
were then immersed in 0.03 mol L
71 citrate buffer (pH 6.0) and
incubated at 958C for 40 min in a water bath for antigen retrieval.
After rinsing in phosphate-buffered saline pH 7.2 (PBS), 10%
bovine serum (Wako, Osaka, Japan) was applied for 20 min to
block nonspeciﬁc reactions. The sections were then incubated with
the primary antibody overnight at 48C. After rinsing in PBS, they
were treated with peroxidase-labelled anti-rabbit immunoglobulins
(Nichirei, Tokyo, Japan) for 30 min. The peroxidase reaction was
visualised by incubating the sections with 0.02% 3,3'-diaminoben-
zidine tetrahydrochloride in 0.05 M Tris buffer with 0.01%
hydrogen peroxide (Nichirei, Tokyo, Japan). The sections were
counterstained with haematoxylin. Sections for the negative control
were prepared using rabbit immunoglobulins instead of the
primary antibody.
Immunohistochemical evaluation
We regarded cells as immunoreactive when the staining signal was
clearly observed in their cytoplasms. We scored immunoreacitivity
as follows: (7) less than 10% of cells were immunoreactive; (+)
10–25% of cells were immunoreactive; (++) 25–50% of cells were
immunoreactive, and (+++) more than 50% of cells were immu-
noreactive. The (++) and (+++) cases were considered as
positive for caveolin-1.
Statistical analyses
Chi-square analysis was employed to analyse the relationship
between caveolin-1 expression and the pathological classiﬁcation
of thyroid neoplasms. A P value of less than 0.05 was considered
to be statistically signiﬁcant.
RESULTS
Caveolin-1 immunoreactivity was frequently present in the
endothelial cells in blood vessels in the stroma, which were recog-
nised as an internal positive control. Follicular cells of normal
thyroid tissue did not express caveolin-1 (Figure 1A). We then
investigated caveolin-1 expression in various types of thyroid
neoplasm (Table 1). Of the 85 papillary carcinomas, 57 cases
(67.1%) were judged as positive for caveolin-1. Especially in micro-
cancers, caveolin-1 was positive in all the cases except one (Figure
1B). Of the remaining two types of papillary carcinoma, cases with
a pure papillary structure, classiﬁed as type A, were more
frequently positive than those with other growth patterns (type
B) (Figure 1C,D). In anaplastic (undifferentiated) carcinomas, only
four cases (12.5%) were positive for caveolin-1, which was signiﬁ-
cantly lower than in type B papillary carcinomas (Figure 1E).
We also examined caveolin-1 expression in tumours of follicular
type, that is, 11 cases of follicular adenoma, 18 cases of minimally
invasive follicular carcinoma and 15 cases of widely invasive folli-
cular carcinoma. However, in contrast to the papillary
carcinomas, caveolin-1 immunoreactivity was not seen in the
tumour cells of these tissues, and all these cases were classiﬁed as
negative, regardless of histological type (Figure 1F).
DISCUSSION
In this study, we have demonstrated that caveolin-1 was frequently
positive in papillary carcinoma, but not in tumours of the follicular
type. In papillary carcinomas, caveolin-1 was more frequently posi-
tive in microcancers than those of larger size, indicating that
caveolin-1 expression is an early event in papillary carcinoma. An
additional more important ﬁnding is that caveolin-1 expression
signiﬁcantly decreased in undifferentiated (anaplastic) carcinomas.
Anaplastic carcinomas can arise from follicular carcinoma as well
as papillary carcinoma, but most are thought to be from papillary
carcinoma, because papillary carcinoma is far more common than
follicular carcinoma. These results allow us to hypothesise that, in
papillary carcinoma, caveolin-1 works as a negative regulator of
carcinoma progression and the lack of or decreased expression of
this protein is linked to the increase in biological aggressiveness.
The reduced expression of caveolin-1 in type B carcinomas
compared to type A carcinomas is also reasonable because cases
with type B histology were reported to show a poorer prognosis
than pure papillary carcinomas (type A), although it is still an open
question whether type B cases actually represent dedifferentiation
as proposed by Sakamoto et al (1983).
The function of caveolin-1 has been intensively investigated by
many researchers. Engelman et al (1998b) have demonstrated that
caveolin-1 negatively regulates the activity of p42/44 MAP kinase,
with the result that caveolin-1 dramatically inhibits signalling from
EGF-R, Raf, MEK-1 and ERK-2 to the nucleus. Furthermore, simi-
lar relationships were observed between caveolin-1 and
heterotrimeric G proteins (Li et al, 1995), c-Src tyrosine kinase
(Song et al, 1997b) and nitric oxide synthase (Garcia-Cardena et
al, 1997), and all these phenomena are mediated through the
caveolin-scaffolding domain. Similar results have also been
obtained for signal transduction from c-erbB-2 (Engelman et al,
1998c) and vascular endothelial growth factor receptor (VEGF-R)
(Lui et al, 1999). As EGF-R (van der Laan et al, 1995), VEGF
and VEGF-R (Klein et al, 1999) as well as c-erbB-2 (Utrilla et al,
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Table 1 Expression of caveolin-1 in thyroid neoplasms
Caveolin-1 expression
Caveolin-1
Negative Positive
immunoreactivity 7 + ++ +++ Total
Anaplastic (undifferentiated 20 8 2 2 32
carcinoma)
Type B papillary carcinoma 11 8 7 5 31
Type A papillary carcinoma 2 6 10 13 31
Microcancer 0 1 6 16 23
Widely invasive follicular 15 0 0 0 15
carcinoma
Minimally invasive follicular 18 0 0 0 18
carcinoma
Follicular adenoma 11 0 0 0 11
P=0.0169 (anaplastic carcinoma vs type B papillary carcinoma); P=0.0048 (type B
papillary carcinoma vs type A papillary carcinoma); P=0.0364 (type A papillary
carcinoma vs microcancer).
Caveolin-1 in thyroid carcinoma
Y Ito et al
914
British Journal of Cancer (2002) 86(6), 912–916 ã 2002 Cancer Research UK1999) are known to be frequently present in papillary carcinoma,
these data support the above hypothesis. In contrast, the aberrant
expression of c-erbB-2, VEGF, basic FGF and hepatocyte growth
factors, as well as inactivation of p53, can, in turn, down-regulate
caveolin-1 (Engelman et al, 1998c; Lui et al, 1999; Razani et al,
2000). Furthermore, when EGF-R binds to EGF, it can move out
of the caveolae with the modulation of Src kinase (Mineo et al,
1999). It is therefore suggested that the abundant expression of
various growth factors and the inactivation of tumour suppressor
genes, such as p53, may cause the down-regulation or decreased
expression of caveolin-1. Regarding the molecular mechanism of
down-regulation of caveolin-1, Cui et al (2001), have reported
hypermethylation of the caveolin-1 gene promoter in prostate carci-
noma and also, mutation of the caveolin-1 gene has been identiﬁed
in scirrhous breast carcinomas (Hayashi et al, 2001). Further
studies of this subject should be carried out on various carcinomas.
On the other hand, caveolin-1 is phosphorylated at tyrosin-14
by c-Src kinase and binds to growth factor receptor-binding
protein 7, which results in anchorage-independent growth and
EGF-stimulated cell migration (Lee et al, 2000). This indicates
the possibility that caveolin-1 not only inhibits but also stimulates
carcinoma progression and metastasis. In prostate carcinoma, Yang
et al (1999) have demonstrated that caveolin-1 expression is
directly related to the Gleason score, positive surgical margin and
lymph node metastasis, and it independently predicts a worse prog-
nosis for patients. They also showed that caveolin-1 can be secreted
and can contribute to metastasis in androgen-insensitive prostate
carcinoma in an autocrine/paracrine fashion (Tahir et al, 2001).
It is therefore suggested that the function of caveolin-1 is not
uniform in carcinoma, depending on the origin of the carcinoma
and on the expression status of various growth factors and
hormones. Studies regarding the secreted type of caveolin-1 in
thyroid carcinoma will be necessary in the future.
Interestingly, in follicular tumours, no caveolin-1 expression was
observed in any cases, regardless of histological type. It is therefore
suggested that the regulation of caveolin-1 does not act on or
against the progression of follicular tumours. As there is no striking
difference between the prognosis of patients with follicular carcino-
ma and papillary carcinoma, regulation of some other type than
caveolin-1 must operate for signal transduction in follicular carci-
nomas. A previous study observed that c-erbB-2 oncoprotein was
expressed in more than 50% of papillary carcinomas but not in
follicular carcinomas or undifferentiated carcinomas (Utrilla et al,
1999). The difference in the status of these proteins in papillary
and follicular carcinomas reﬂects the difference of entities between
these two types of carcinoma.
In summary, this study indicates that, in papillary carcinomas,
caveolin-1 plays a role in the early phase and its decreased expres-
sion is linked to aggressive characteristics including de-
differentiation. Further studies should be carried out regarding
the mechanism of function and/or the lack of function of
caveolin-1 in thyroid carcinoma.
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